A retrospective study of the efficacy of sulbactam in the treatment of patients with extensively drug-resistant Acinetobacter baumannii infections
Infection · 2024
DOI: 10.1007/s15010-024-02307-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection, 2024. Verfasst von Jiaxin Yu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of pharmacy & State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, No.1 Shuaifuyuan Wangfujing…. Hauptthemen laut MEDLINE: Sulbactam, Acinetobacter baumannii, Acinetobacter Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Sulbactam (SBT) is one of the most significant treatments for patients with extensively drug-resistant Acinetobacter baumannii (XDR-AB). However, the efficacy and safety of SBT and its high dose regimen has not been well documented. This retrospective study aimed to assess the efficacy and safety of SBT-based treatment, particularly at high-dose (≥ 6 g/day), for XDR-AB infection.
Method
A total of 52 XDR-AB infected patients treated with intravenous SBT at Peking Union Medical College Hospital were included. The primary outcome was 28-day all-cause mortality, while the secondary outcome was 14-day clinical response and the time of response. The formulation of SBT in our study is 0.5 g per vial.
Results
Among the patients, the 28-day all-cause mortality rate was 36.5% (19/52), and the favorable 14-day clinical response rate was 59.6% (31/52). The 28-day mortality was independently associated coinfection with gram-positive bacteria (GPB) and a shorter duration of therapy. Patients with intracranial infection might have a longer survival time. A favorable 14-day clinical response was associated with the dose of SBT, and a longer treatment duration. However, the higher creatinine clearance (CrCl) associated with a worse clincal response. In addition, a higher SBT dosage was significantly correlated with a shorter time to clinical response. No adverse effects related were reported.
Conclusion
The single-agent formulation of SBT emerges as a promising alternative for the treatment of XDR-AB infection, such as intracranial infection, particularly at high doses (≥ 6 g/day). Besides, longer duration of treatment correlates with higher survival rate and better favorable clinical response. Higher CrCl negatively correlates with favorable clinical response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of pharmacy & State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing, 100730, China.
- School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
- School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
- Department of pharmacy & State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing, 100730, China. eileenzuo@163.com.
- Department of pharmacy & State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing, 100730, China. zhangbopumch@163.com.
Zitieren
APA
Yu, J., Zhang, B., Yang, Y., Dou, W., Li, Y., Yang, A., Ruan, X., Zuo, W., & Zhang, B. (2024). A retrospective study of the efficacy of sulbactam in the treatment of patients with extensively drug-resistant Acinetobacter baumannii infections. Infection. https://doi.org/10.1007/s15010-024-02307-9
Vancouver
Yu J, Zhang B, Yang Y, Dou W, Li Y, Yang A, et al. A retrospective study of the efficacy of sulbactam in the treatment of patients with extensively drug-resistant Acinetobacter baumannii infections. Infection. 2024. doi:10.1007/s15010-024-02307-9
BibTeX
@article{Yu2024,
author = {Yu, Jiaxin and Zhang, Baoshuang and Yang, Yang and Dou, Wei and Li, Yuliu and Yang, Anji and Ruan, Xiao and Zuo, Wei and Zhang, Bo},
title = {A retrospective study of the efficacy of sulbactam in the treatment of patients with extensively drug-resistant Acinetobacter baumannii infections},
journal = {Infection},
year = {2024},
doi = {10.1007/s15010-024-02307-9}
}
EUVIMED